Dip in margin along with the lower other income compared to last quarter resulted into lower than top line growth in PAT; reported PAT accelerated by 23.3% to Rs10.1bn
January 01, 1970 5:30 IST | India Infoline News Service
CMP Rs999, Target Rs1,064, Upside 6.5%
Revenue growth of 32.5% yoy and 7.7% qoq to Rs30.9bn was ~8% better than our estimate
The growth was primarily on the back higher realistaion of rupee and full integration of Dusa and URL
Domestic market adjusting for base of last year grew healthy by 16.3% yoy to Rs7.7bn
US Formulation clocked in strong revenue growth of 76% yoy to Rs17.4bn; largely led by full integration of its acquired companies and better realsiation
Operating margins declined 316bps qoq and increased 26bps qoq to 41.3%; Margins are strong even after the integration of the acquired companies
Dip in margin along with the lower other income compared to last quarter resulted into lower than top line growth in PAT; reported PAT accelerated by 23.3% to Rs10.1bn
Sun Pharma board recommended issue of bonus shares in the ratio of 1:1
Company has guided for 18-20% growth for FY14. We believe going forward, approval of generic version of Doxil, niche launches and integration of DUSA Pharma & URL will keep the thrust on going in the US market. We remain positive on the company but on a limited upside potential, we downgrade our rating to MP with a revise target of Rs1,064.
Result table
(Rs mn)
Q4 FY13
Q4 FY12
% yoy
Q3 FY13
% qoq
Operating Income
30,870
23,299
32.5
28,655
7.7
Inc/(dec) in stock
(491)
(1,073)
(54.3)
102
(583.4)
Consumption of Materials
(5,463)
(4,960)
10.1
(4,251)
28.5
Purchase of Traded Goods
(323)
(1,022)
(68.3)
(1,241)
(73.9)
Employees' Cost
(4,394)
(3,480)
26.3
(3,871)
13.5
Other Expenditure
(8,427)
(5,346)
57.6
(6,445)
30.7
Operating profit
12,754
9,565
33.3
12,745
0.1
OPM (%)
41.3
41.05
26 bps
44.48
(316) bps
Depreciation
(887)
(823)
7.9
(844)
5.1
Interest income
(72)
(112)
(36.2)
123
(158.1)
Other income
1,018
2,181
(53.3)
678
50.1
PBT
12,814
10,811
18.5
12,703
0.9
Tax
(1,773)
(1,768)
0.3
(2,369)
(25.1)
Effective tax rate (%)
13.8
16.4
(252) bps
19
(481) bps
PAT
11,041
9,043
22.1
10,334
6.8
Min Interest & other Adj
925
841
10.0
1,521
(39.2)
Reported PAT
10,116
8,202
23.3
8,813
14.8
PAT margin (%)
32.8
35.20
(243) bps
30.8
201 bps
Ann. EPS (Rs)
39.1
31.7
23.3
34.0
14.8
Source: Company, India Infoline Research
Revenue growth of 32.5% yoy and 7.7% qoq to Rs30.9bn was ~8% better than our estimate
Revenue growth of 32.5% yoy and 7.7% qoq to Rs30.9bn was ~8% better than our estimates largely led by full integration of its acquired companies. The growth in revenues was primarily led by higher than the expected growth in its US. US Formulation clocked in strong revenue growth of 76% yoy to Rs17.4bn; largely led by full integration of its acquired companies and better realsiation. Domestic market adjusting for base of last year grew healthy by 16.3% yoy to Rs7.7bn. Formulation sales in rest of the world (ROW) markets outside of India and US accounted for Rs3.9bn in Q4 FY13 registering a growth of 22% . API business which is largely for captive purpose, also, continues to grow. External sales of API grew by 11% yoy to Rs1.6bn in Q4 FY13.
Revenue Break-up
Rsmn.
Q4FY13
Q4FY12
% yoy
Q3FY13
% qoq
India Formulations
7,797
8,767
(11.1)
7,885
(1.1)
US Formulations
17,879
10,106
76.9
14,946
19.6
ROW Formulations
3,937
3,226
22.1
3,942
(0.1)
Export Formulation
21,816
13,332
63.6
18,888
15.5
Total Formulations
29,614
22,099
34.0
26,773
10.6
Bulk
1,699
1,531
11.0
2,090
(18.7)
Others
(130)
8
-
59
-
Total Sales
31,183
23,638
31.9
28,922
7.8
US Formulation clocked in strong revenue growth of 76% yoy to Rs17.4bn; largely led by full integration of its acquired companies and better realsiation
Sales in the US were US$330mn for Q4FY13, up by 63%, and accounted for 57% of total sales. In Q4 FY13, there was a full consolidation of the DUSA acquisition, while the URL acquisition was consolidated for 2 months. Taro, the US subsidiary, recorded sales of US$165mn in this quarter, up 14% yoy. The Net profit for Q4 was US$49mn which had post provision of US$55mn for settlements and loss contingencies. Both for the fourth quarter and FY13 volumes declined marginally. During the quarter, the URL acquisition achieved financial closure. The non-Colcrys (Colchicine, USP) generic assets of URL Pharma are now owned and managed by Sun (107 products represented by over 230 ANDAs). In February, the US FDA granted the final approval for Doxorubicin HCl Liposomal injection and company launched the product in current quarter. In Q4, 9 ANDAs were filled. As on March 31, the company has filled cumulatively 449 with the USFDA and received approval of 311, excluding 17 tentative approvals. The above ANDA statistics exclude the discontinued/withdrawn products of URL.
Operating margins declined 316bps qoq and increased 26bps qoq to 41.3%; Margins are strong even after the integration of the acquired companies Sun Pharma managed to maintain high operating margin even in this quarter at 41.3%. Taro continue to indicate that the growth may not be sustainable as the higher growth is driven by identifying niche opportunity and some part of growth is attributable to price hike in the products; so with the competition creeping in the growth might not be sustainable. But, even with this comments, Taro continues to surprise. Even if we factor in some weakness at Taro, new niche launches and improving operating parameters at Dusa and URL will keep the margin at the high end of the sector average. In line with sales, Dip in margin along with the lower other income compared to last quarter resulted into lower than top line growth in PAT; reported PAT accelerated by 23.3% to Rs10.1bn.
